Skip to main content
Clinical Trials/NCT02920203
NCT02920203
Unknown
Not Applicable

Genetic Autopsy and Sudden Death of Young Subject

Assistance Publique - Hôpitaux de Paris1 site in 1 country300 target enrollmentOctober 11, 2017
ConditionsSudden Death

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sudden Death
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
300
Locations
1
Primary Endpoint
Comparison of sudden death elucidation rate obtained by high throughput sequencing (NGS) versus conventional autopsy (macroscopic and / or microscopic)
Last Updated
8 years ago

Overview

Brief Summary

The purpose of the study is to better identify hereditary cardiac causes of sudden unexpected death in young subjects through Next-Generation Sequencing of autopsy tissue

Detailed Description

Monitoring : For index cases group, all the data will be monitored. For the relatives group, only the informed consent will be monitored Statistical analysis : * Evaluate the additional elucidation rate of unexpected sudden death * Evaluate causes obtained by Next Generation Sequencing (NGS) ( in comparison with conventional autopsy (macroscopic and / or microscopic) * Descriptive study of the causes of sudden unexpected death, identified hereditary cardiac causes percentages compared via various diagnostic approaches * Cost-effectiveness analysis Data Management : A database is created for the AGEMOS study with control of the discrepancies. All the index cases' data entered in the data base will be double checked

Registry
clinicaltrials.gov
Start Date
October 11, 2017
End Date
December 2020
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects of more than 2 years old and less than 41 years old
  • Sudden unexpected death from natural and nontraumatic causes
  • Macroscopic autopsy performed within 72 hours after death and without signs of body decomposition
  • No extracardiac obvious causes, including toxicological analysis when available
  • No significant coronary cause after autopsy (such as tight coronary stenosis, congenital abnormality of the arteries, coronary vasculitis)
  • Informed consent of the close relation (family/reliable person) and / or legal representative
  • Relatives :
  • Inclusion Criteria:
  • To be a first degree relative (parents, sister, brother, child) of a deceased subject included in the AGEMOS study and accept to perform medical examination and transmit results of examination

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Comparison of sudden death elucidation rate obtained by high throughput sequencing (NGS) versus conventional autopsy (macroscopic and / or microscopic)

Time Frame: 27 months

Aim is to determine if elucidation rate of unexpected sudden death causes obtained by high throughput sequencing (NGS) is significantly better than conventional autopsy (macroscopic and / or microscopic) alone. Inclusion of a series of 100 consecutive and exhaustive cases (index cases) recruited by forensic institutes or pathology departements. Determine the rate of sudden death elucidation after NGS (after targeted capturing of 100 genes responsible for inherited cardiac diseases, including cardiomyopathy and electrical diseases) and comparison of sudden death elucidation rate obtained with conventional autopsy (macroscopic and microscopic) by chi 2 analysis.

Secondary Outcomes

  • Comparison of elucidation rates of cause of sudden death including systematic cardiac screening in relatives(39 months)
  • Describe the epidemiology of causes of sudden death(27 months)
  • Medico-economic modeling of the various diagnostic approaches(39 months)

Study Sites (1)

Loading locations...

Similar Trials